Therapeutic potential of the Peptide leucine arginine as a new nonplant bowman-birk-like serine protease inhibitor.

The peptide leucine arginine (pLR) belongs to a new class of cyclic peptides isolated from frog skin. Its primary sequence is similar to the reactive loop of plant Bowman-Birk inhibitors (BBI), and the recently discovered circular sunflower trypsin inhibitor-1 (SFTI-1). The conformational properties of pLR in solution were determined by NMR spectroscopy and revealed excellent structural similarity to BBI and SFTI-1. Moreover, pLR is a highly potent trypsin inhibitor, with Ki values in the nanomolar range, and, due to its small size, a potential inhibitor of the serine protease tryptase. Since tryptase plays a crucial role in the development of allergic airway inflammation, the therapeutic potential of pLR in a murine asthma model was investigated. Treatment of ovalbumin-sensitized mice with pLR during allergen challenge reduced the acute asthma phenotype. Most importantly, application even at the end of a long-lasting chronic asthma model decreased the development of chronic airway inflammation and tissue remodeling.

Citation

Sven Rothemund, Frank D Sönnichsen, Tobias Polte. Therapeutic potential of the Peptide leucine arginine as a new nonplant bowman-birk-like serine protease inhibitor. Journal of medicinal chemistry. 2013 Sep 12;56(17):6732-44

PMID: 23988198

search → result